Experience on switching trientine formulations in Wilson disease: Efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl.
Wilson disease
trientine dihydrochloride (TETA 2HCl)
trientine tetrahydrochloride (TETA 4 HCl)
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
27
09
2022
received:
06
03
2022
accepted:
01
11
2022
pubmed:
5
11
2022
medline:
10
2
2023
entrez:
4
11
2022
Statut:
ppublish
Résumé
This retrospective, multicenter study aims to assess the efficacy and safety in Wilson disease (WD) patients treated with trientine tetrahydrochloride (TETA 4HCl) after switch from trientine dihydrochloride (TETA 2HCl). In total, 68 WD patients with stable copper metabolism were identified to receive TETA 4HCl (Cuprior™) after previous treatment with TETA 2HCl. We analyzed biochemical markers such as urinary copper, serum copper, non-coeruloplasmin bound copper (NCC), and transaminases as well as clinical scores (APRI; FIB-4 score) at baseline with a follow-up (FU) of 12 months. Safety of TETA 4HCl treatment was based on reported adverse events (AEs). The study cohort reflects a common WD cohort with a mean age of 20.3 years at diagnosis and 38.3 years at baseline. There are no significant differences concerning serum copper, NCC, transaminases, APRI, and FIB-4 score in the 3-month FU. Six-month FU revealed a decreased AST (P = 0.008), APRI (P = 0.042), and FIB-4 score (P = 0.039). GGT varied only borderline significantly in the 3-month, but not in the 6-month FU. Comparison of urinary copper within the subsets did not reveal a difference to baseline in all FUs, suggesting stable control of copper metabolism. Few AEs during TETA 4HCl treatment were reported, most commonly gastrointestinal discomfort. Only three treatments with TETA 4HCl were discontinued. Copper parameters and liver function were stable after treatment switch to TETA 4HCl. Treatment with TETA 4HCl was generally well tolerated. This study indicates that the switch from TETA 2HCl to TETA 4HCl is safe and viable.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
This retrospective, multicenter study aims to assess the efficacy and safety in Wilson disease (WD) patients treated with trientine tetrahydrochloride (TETA 4HCl) after switch from trientine dihydrochloride (TETA 2HCl).
METHODS
METHODS
In total, 68 WD patients with stable copper metabolism were identified to receive TETA 4HCl (Cuprior™) after previous treatment with TETA 2HCl. We analyzed biochemical markers such as urinary copper, serum copper, non-coeruloplasmin bound copper (NCC), and transaminases as well as clinical scores (APRI; FIB-4 score) at baseline with a follow-up (FU) of 12 months. Safety of TETA 4HCl treatment was based on reported adverse events (AEs).
RESULTS
RESULTS
The study cohort reflects a common WD cohort with a mean age of 20.3 years at diagnosis and 38.3 years at baseline. There are no significant differences concerning serum copper, NCC, transaminases, APRI, and FIB-4 score in the 3-month FU. Six-month FU revealed a decreased AST (P = 0.008), APRI (P = 0.042), and FIB-4 score (P = 0.039). GGT varied only borderline significantly in the 3-month, but not in the 6-month FU. Comparison of urinary copper within the subsets did not reveal a difference to baseline in all FUs, suggesting stable control of copper metabolism. Few AEs during TETA 4HCl treatment were reported, most commonly gastrointestinal discomfort. Only three treatments with TETA 4HCl were discontinued.
CONCLUSION
CONCLUSIONS
Copper parameters and liver function were stable after treatment switch to TETA 4HCl. Treatment with TETA 4HCl was generally well tolerated. This study indicates that the switch from TETA 2HCl to TETA 4HCl is safe and viable.
Substances chimiques
Trientine
SJ76Y07H5F
Copper
789U1901C5
Chelating Agents
0
Transaminases
EC 2.6.1.-
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
219-224Subventions
Organisme : Orphalan S.A.
Informations de copyright
© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Walshe JM. History of Wilson's disease: 1912 to 2000. Mov. Disord. 2006; 21: 142-147.
Walshe JM. History of Wilson disease: a personal account. Handb. Clin. Neurol. 2017; 142: 1-5.
European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J. Hepatol. 2012; 56: 671-685.
Roberts EA, Schilsky ML, American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology 2008; 47: 2089-2111.
Walshe JM. Wilson's disease; new oral therapy. Lancet 1956; 270: 25-26.
Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J. Neurol. Sci. 1987; 77: 137-146.
Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982; 1: 643-647.
Ala A, Aliu E, Schilsky ML. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease. Dig. Dis. Sci. 2015; 60: 1433-1439.
Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N. Engl. J. Med. 1987; 317: 209-213.
Mohr I, Weiss KH. Current anti-copper therapies in management of Wilson disease. Ann. Transl. Med. 2019; 7: S69.
Weiss KH, Thurik F, Gotthardt DN et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin. Gastroenterol. Hepatol. 2013; 11: 1028-1035 e1-2.
Pfeiffenberger J, Kruse C, Mutch P, Harker A, Weiss KH. The steady state pharmacokinetics of trientine in Wilson disease patients. Eur. J. Clin. Pharmacol. 2018; 74: 731-736.
EMA, EPAR Cuprior 2017.
Agency, E.M. CHMP assessment report. [pdf] 2017.
Weiss KH, Thompson C, Dogterom P et al. Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects. Eur. J. Drug Metab. Pharmacokinet. 2021; 46: 665-675.
Paternostro R, Pfeiffenberger J, Ferenci P et al. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int. 2020; 40: 894-904.
Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann. Hepatol. 2009; 8: 26-31.
Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007; 56: 115-120.
Weiss KH. In: Adam MP et al., eds. Wilson Disease, in GeneReviews((R)). Seattle (WA), 1993.
Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015; 14: 103-113.